SEPTEMBER 22, 2025
You and a guest are invited to an advance screening of new biotech documentary hosted by the Science History Institute at the Ritz Theater on September 22.
Cracking the Code: Phil Sharp and the Biotech Revolution
Brought to you by the producers of Jim Allison: Breakthrough, Cracking the Code is an inspiring story of vision, perseverance, and the power of science to change the world. Phil Sharp’s journey from a Kentucky farm boy to Nobel laureate embodies the American Dream and the triumph of entrepreneurial spirit. His 1977 groundbreaking discovery of RNA splicing rewrote the rules of molecular biology and ignited a life-saving scientific revolution, laying the foundation for an industry that has become a cornerstone of global innovation and economic growth – and transformed the health of billions of patients worldwide.
Tickets are complimentary for you and a guest.
Please RSVP by 5pm on Monday, September 22
HOSTED BY
ABOUT THE SCIENCE HISTORY INSTITUTE
The Science History Institute is a free museum and library in Old City, Philadelphia, dedicated to preserving, interpreting, and sharing the stories behind the science. For more than 40 years, the Institute has remained committed to public engagement by growing our collections, developing dynamic programs and events, and producing award-winning content.
​
To make a gift in support of dynamic science history storytelling, please visit www.sciencehistory.org/support/.
ABOUT PHIL SHARP
Phillip A. Sharp, PhD, an Institute Professor emeritus at MIT, is a member of the Department of Biology and the Koch Institute for Integrative Cancer Research. His work studying the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing earned Sharp the 1993 Nobel Prize in Physiology for Medicine. Sharp is past President of AAAS, serves on the boards of directors of the Broad Institute, Stand Up 2 Cancer, and the Gairdner Foundation. He is a co-founder of Biogen and of Alnylam Pharmaceuticals and serves on the Scientific Advisory Boards of F-Prime Capital, Alnylam Pharmaceuticals, Danaher, Dewpoint Therapeutics, and Skyhawk Therapeutics, He is also advisor to Longwood and Polaris Venture Funds.
